Isoxazoline Patent Landscape Results
In sections A to C below, we share selected preliminary results for our isoxazoline case study. Section A illustrates a general overview of isoxazoline patent publications (section A1). We further segment the isoxazoline patent landscape by time: results from the last 20 years since 1999 (section A2) and those before from 1955 until 1999 (section A3). Analysis of the isoxazoline patent landscape by timeframe allows one to evaluate how the field has evolved. Interestingly, we find that many of the key players are different between these two timeframes, and most of the isoxazoline patent publications are published in the last 20 years.
In section B, we segment the isoxazoline patent dataset by industry and focus on patent publications relevant to the animal health industry.
A1. Isoxazoline Patent Publications Overview
>3500 isoxazoline patent families were retrieved using PatentInspiration by AULIVE.
A2. Key Isoxazoline Patent Players
B1. Isoxazolines Patent Landscape in Animal Health
•Who are the key players and their collaborators?
•What are the main applications and hosts?
•Who are the key academic organizations? Who do they collaborate with?
•What are the main themes and trends (segmented by geography, year or patent topics)?
•What are the target parasites?
•What are the administration modes?
•Is a specific isoxazoline long or short acting?
B2. Selected results in Animal Health
A. Number of Patent Publications
> 220 patent families were retrieved, including those relevant to current isoxazoline commercial products.
B. Scientific Topics
The scientific competences of the animal health isoxazoline patent publications are rather diverse. These include new isoxazoline molecules, synthesis methods, applications, compositions and route of administrations. The patent in section D describes a new method of isoxazoline synthesis.
C. Key Animal Health Industrial Players
These include the four veterinary companies commercializing isoxazolines, their R&D partners and others. For example, Fluralaner (brand name Bravecto) is sold by Merck Animal Health in the US and by MSD Animal Health in Europe. This is a collaboration between MSD Animal Health and Nissan Chemical Corporation, who first invented fluralaner. We also retrieved isoxazoline animal health patents from Nissan Chemical Corporation.
D. Academic Players
There are academic laboratories working on diverse aspects of isoxazolines. Patent number WO2018191871A1 is an example for patents in the academic players category.
Method For Use In Preparing Isoxazoline Derivative
2018 By Zhangjiagang Institute of Industrial Technologies
This patent is one of the most recent isoxazoline patent applications, and it describes a method to synthesize isoxazolines. Though most of the isoxazoline patent applicants are from commercial organizations, the applicant of this patent is from an academic research organization.
E. New Host and Applications of Isoxazolines
There are several host or application patent publications. Patent number WO2015091900A1 is an example patent with new host and application for isoxazolines.
Use Of Isoxazoline Derivatives For The Treatment Or Prevention Of Arthropod Infestations In Poultry
This patent describes a new isoxazoline application beyond cats and dogs; here, the main host animal is poultry. This patent is about method of treating or preventing arthropod infestations of poultry animals by using a composition containing an isoxazoline compound, for example in medicated drinking water.
•Isoxazolines have long innovation history (>60 years) in diverse scientific fields, including in agriculture-crop protection, chemical, agrochemical, animal health and pharmaceutical industries.
•Isoxazolines have high innovation potentials for additional applications in and beyond the animal health industry.
•A recent study by scientists at Calibr and TropiQ Health Sciences (Miglianico et al, PNAS, 2018, 115(29):E6920) demonstrated the potential of isoxazolines as insecticides to prevent outbreaks of malaria, zika virus and other insect borne diseases.
•By segmenting the isoxazoline patent dataset by industry and additional variables, we were able to extract insights that are distinct for each variable which further provide opportunities for cross-industry learnings and benchmarking analyses.
•Important (September 2018): The U.S Food and Drug Administration (FDA) issued an alert to pet owners and veterinarians about the potential for neurologic adverse events in dogs and cats when treated with the isoxazoline class of drugs. FDA noted that some animals receiving Bravecto, Nexgard or Simparica have experienced adverse events such as muscle tremors, ataxia, and seizures. These products have been approved by FDA for treatment and management of flea and tick infestations. Another product in this class, Credelio, has recently been approved by FDA. These products continue to be safe and effective for the majority of animals. FDA is working with manufacturers of isoxazoline products to include new label information to highlight neurologic events, because these events were seen consistently across the isoxazoline class of products.